IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ET
Company Overview: IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on premium cannabis products for medical patients in these significant markets.
Financial Reporting: The company will announce its operational and financial results for the third quarter of 2025 on November 13, 2025, prior to market opening.
Ecosystem and Operations: IMC operates a comprehensive ecosystem in Israel, including subsidiaries that import and distribute cannabis, as well as retail pharmacies and online platforms, ensuring quality control and safe delivery.
Commitment to Growth: IMC aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced supply chain while adhering to strict regulatory standards.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on IMCC
About IMCC
About the author

IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.

IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.






